25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Jin Yang Pharmaceutical Co. Ltd
Buy, Hold or Sell?

Let's analyze Jin Yang Pharmaceutical Co. Ltd together

I guess you are interested in Jin Yang Pharmaceutical Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jin Yang Pharmaceutical Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Jin Yang Pharmaceutical Co. Ltd

I send you an email if I find something interesting about Jin Yang Pharmaceutical Co. Ltd.

Quick analysis of Jin Yang Pharmaceutical Co. Ltd (30 sec.)










What can you expect buying and holding a share of Jin Yang Pharmaceutical Co. Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.10
When do you have the money?
1 year
How often do you get paid?
82.1%

What is your share worth?

Current worth
₩8,336.51
Expected worth in 1 year
₩9,367.38
How sure are you?
92.9%

+ What do you gain per year?

Total Gains per Share
₩1,180.86
Return On Investment
20.5%

For what price can you sell your share?

Current Price per Share
₩5,750.00
Expected price per share
₩5,020 - ₩5,708
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Jin Yang Pharmaceutical Co. Ltd (5 min.)




Live pricePrice per Share (EOD)

₩5,750.00

Intrinsic Value Per Share

₩13,592.28 - ₩16,168.64

Total Value Per Share

₩21,928.79 - ₩24,505.15

2. Growth of Jin Yang Pharmaceutical Co. Ltd (5 min.)




Is Jin Yang Pharmaceutical Co. Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$62.8m$52.7m$8.2m13.6%

How much money is Jin Yang Pharmaceutical Co. Ltd making?

Current yearPrevious yearGrowGrow %
Making money$2m$2.3m-$277.6k-13.5%
Net Profit Margin12.2%16.2%--

How much money comes from the company's main activities?

3. Financial Health of Jin Yang Pharmaceutical Co. Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Jin Yang Pharmaceutical Co. Ltd? (5 min.)

Welcome investor! Jin Yang Pharmaceutical Co. Ltd's management wants to use your money to grow the business. In return you get a share of Jin Yang Pharmaceutical Co. Ltd.

What can you expect buying and holding a share of Jin Yang Pharmaceutical Co. Ltd?

First you should know what it really means to hold a share of Jin Yang Pharmaceutical Co. Ltd. And how you can make/lose money.

Speculation

The Price per Share of Jin Yang Pharmaceutical Co. Ltd is ₩5,750. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jin Yang Pharmaceutical Co. Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jin Yang Pharmaceutical Co. Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩8,336.51. Based on the TTM, the Book Value Change Per Share is ₩257.72 per quarter. Based on the YOY, the Book Value Change Per Share is ₩352.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩37.50 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jin Yang Pharmaceutical Co. Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.120.0%0.190.0%0.220.0%0.130.0%0.080.0%
Usd Book Value Change Per Share0.030.0%0.180.0%0.250.0%0.160.0%0.210.0%
Usd Dividend Per Share0.000.0%0.030.0%0.050.0%0.050.0%0.050.0%
Usd Total Gains Per Share0.030.0%0.210.0%0.300.0%0.210.0%0.260.0%
Usd Price Per Share4.16-4.26-4.18-4.31-3.98-
Price to Earnings Ratio8.57-8.26-6.78-2.47-12.37-
Price-to-Total Gains Ratio165.11-54.19-25.35-52.75-77.17-
Price to Book Ratio0.71-0.75-0.86-1.16-1.16-
Price-to-Total Gains Ratio165.11-54.19-25.35-52.75-77.17-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.025
Number of shares248
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.05
Usd Book Value Change Per Share0.180.16
Usd Total Gains Per Share0.210.21
Gains per Quarter (248 shares)51.2553.09
Gains per Year (248 shares)205.00212.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12617919554158202
252358400108317414
378537605162475626
4104716810216633838
513089510152707911050
6156107412203249501262
71821253142537911081474
82081432163043312661686
92341611183548714251898
102601790204054115832110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%24.04.00.085.7%24.04.00.085.7%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%17.03.00.085.0%22.06.00.078.6%22.06.00.078.6%
Dividend per Share1.00.03.025.0%7.00.05.058.3%15.00.05.075.0%23.00.05.082.1%23.00.05.082.1%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%26.02.00.092.9%26.02.00.092.9%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Jin Yang Pharmaceutical Co. Ltd

About Jin Yang Pharmaceutical Co. Ltd

Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers products for anti-diabetics, antivirals, anti-hypertensives, anti-coagulants, antihistamines, antipyretics, and analgesics; digestive, respiratory, and neuropsychiatric system. It also provides drugs for genito-urinary system, anti-osteoporosis drugs, antimicrobials and antibiotics; and over the counter drugs antipyretics and analgesics. It also provides products for digestive, genito-urinary, neuropsychiatric, circulatory, and dermatological system. In addition, the company offers products for muscle relaxants, anti-hyperlipidemics, multivitamins and nutritionals, hepatics, anti-anemics, anti-obesity drugs, dental care drugs, and ophthalmic drugs. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is based in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-07-13 00:55:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Jin Yang Pharmaceutical Co. Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jin Yang Pharmaceutical Co. Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 6.8% means that ₩0.07 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 6.8%. The company is making a profit. +1
  • The TTM is 12.2%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ6.8%TTM12.2%-5.4%
TTM12.2%YOY16.2%-4.0%
TTM12.2%5Y10.7%+1.5%
5Y10.7%10Y6.5%+4.2%
1.1.2. Return on Assets

Shows how efficient Jin Yang Pharmaceutical Co. Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Assets means that Jin Yang Pharmaceutical Co. Ltd generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM2.4%-0.9%
TTM2.4%YOY3.0%-0.6%
TTM2.4%5Y2.1%+0.3%
5Y2.1%10Y1.3%+0.8%
1.1.3. Return on Equity

Shows how efficient Jin Yang Pharmaceutical Co. Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.1% Return on Equity means Jin Yang Pharmaceutical Co. Ltd generated ₩0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 2.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.1%TTM3.4%-1.4%
TTM3.4%YOY4.5%-1.0%
TTM3.4%5Y3.0%+0.4%
5Y3.0%10Y1.8%+1.2%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Jin Yang Pharmaceutical Co. Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jin Yang Pharmaceutical Co. Ltd is operating .

  • Measures how much profit Jin Yang Pharmaceutical Co. Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY11.1%-11.1%
TTM-5Y4.9%-4.9%
5Y4.9%10Y2.2%+2.7%
1.2.2. Operating Ratio

Measures how efficient Jin Yang Pharmaceutical Co. Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.28 means that the operating costs are ₩1.28 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 1.280. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.182. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.280TTM1.182+0.098
TTM1.182YOY0.829+0.352
TTM1.1825Y0.838+0.344
5Y0.83810Y1.030-0.192
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Jin Yang Pharmaceutical Co. Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jin Yang Pharmaceutical Co. Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.85 means the company has ₩1.85 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 1.853. The company is able to pay all its short-term debts. +1
  • The TTM is 1.808. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.853TTM1.808+0.045
TTM1.808YOY1.521+0.287
TTM1.8085Y1.613+0.195
5Y1.61310Y1.524+0.089
1.3.2. Quick Ratio

Measures if Jin Yang Pharmaceutical Co. Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.00 means the company can pay off ₩1.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 1.004. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.072. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.004TTM1.072-0.068
TTM1.072YOY1.335-0.263
TTM1.0725Y1.205-0.133
5Y1.20510Y1.104+0.101
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Jin Yang Pharmaceutical Co. Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jin Yang Pharmaceutical Co. Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.28 means that Jin Yang Pharmaceutical Co. Ltd assets are financed with 27.7% credit (debt) and the remaining percentage (100% - 27.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 0.277. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.287. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.277TTM0.287-0.010
TTM0.287YOY0.326-0.039
TTM0.2875Y0.325-0.038
5Y0.32510Y0.347-0.022
1.4.2. Debt to Equity Ratio

Measures if Jin Yang Pharmaceutical Co. Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 38.3% means that company has ₩0.38 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The MRQ is 0.383. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.405. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.383TTM0.405-0.022
TTM0.405YOY0.485-0.080
TTM0.4055Y0.488-0.082
5Y0.48810Y0.541-0.053
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Jin Yang Pharmaceutical Co. Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Jin Yang Pharmaceutical Co. Ltd generates.

  • Above 15 is considered overpriced but always compare Jin Yang Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 8.57 means the investor is paying ₩8.57 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The EOD is 8.298. Based on the earnings, the company is underpriced. +1
  • The MRQ is 8.572. Based on the earnings, the company is underpriced. +1
  • The TTM is 8.256. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD8.298MRQ8.572-0.274
MRQ8.572TTM8.256+0.316
TTM8.256YOY6.783+1.473
TTM8.2565Y2.474+5.782
5Y2.47410Y12.373-9.899
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The EOD is 5.094. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.262. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 13.917. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.094MRQ5.262-0.168
MRQ5.262TTM13.917-8.654
TTM13.917YOY21.192-7.275
TTM13.9175Y21.893-7.976
5Y21.89310Y20.242+1.651
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jin Yang Pharmaceutical Co. Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.71 means the investor is paying ₩0.71 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Jin Yang Pharmaceutical Co. Ltd:

  • The EOD is 0.690. Based on the equity, the company is cheap. +2
  • The MRQ is 0.713. Based on the equity, the company is cheap. +2
  • The TTM is 0.755. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.690MRQ0.713-0.023
MRQ0.713TTM0.755-0.042
TTM0.755YOY0.865-0.110
TTM0.7555Y1.164-0.409
5Y1.16410Y1.165-0.001
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Jin Yang Pharmaceutical Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--35.975257.716-86%352.399-90%227.952-84%297.733-88%
Book Value Per Share--8336.5138083.602+3%6931.230+20%5683.428+47%5177.659+61%
Current Ratio--1.8531.808+3%1.521+22%1.613+15%1.524+22%
Debt To Asset Ratio--0.2770.287-4%0.326-15%0.325-15%0.347-20%
Debt To Equity Ratio--0.3830.405-5%0.485-21%0.488-21%0.541-29%
Dividend Per Share---37.500-100%76.865-100%77.873-100%69.912-100%
Eps--173.236272.934-37%307.163-44%184.515-6%120.280+44%
Free Cash Flow Per Share--282.204192.905+46%47.887+489%117.411+140%86.971+224%
Free Cash Flow To Equity Per Share--282.204150.302+88%-84.413+130%47.277+497%22.959+1129%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--16168.637--------
Intrinsic Value_10Y_min--13592.276--------
Intrinsic Value_1Y_max--641.716--------
Intrinsic Value_1Y_min--629.745--------
Intrinsic Value_3Y_max--2673.823--------
Intrinsic Value_3Y_min--2537.598--------
Intrinsic Value_5Y_max--5605.002--------
Intrinsic Value_5Y_min--5138.235--------
Market Cap61959700000.000-3%64007117460.00065676516545.000-3%64941993375.000-1%67905091444.000-6%62983264245.714+2%
Net Profit Margin--0.0680.122-44%0.162-58%0.107-36%0.065+6%
Operating Margin----0%0.111-100%0.049-100%0.022-100%
Operating Ratio--1.2801.182+8%0.829+54%0.838+53%1.030+24%
Pb Ratio0.690-3%0.7130.755-6%0.865-18%1.164-39%1.165-39%
Pe Ratio8.298-3%8.5728.256+4%6.783+26%2.474+246%12.373-31%
Price Per Share5750.000-3%5940.0006092.500-3%5972.500-1%6151.000-3%5689.107+4%
Price To Free Cash Flow Ratio5.094-3%5.26213.917-62%21.192-75%21.893-76%20.242-74%
Price To Total Gains Ratio159.831-3%165.11254.188+205%25.346+551%52.754+213%77.168+114%
Quick Ratio--1.0041.072-6%1.335-25%1.205-17%1.104-9%
Return On Assets--0.0150.024-37%0.030-50%0.021-27%0.013+16%
Return On Equity--0.0210.034-40%0.045-53%0.030-31%0.018+14%
Total Gains Per Share--35.975295.216-88%429.263-92%305.824-88%367.644-90%
Usd Book Value--62881700.73560998531.913+3%52715924.021+19%43715433.703+44%39972548.949+57%
Usd Book Value Change Per Share--0.0250.180-86%0.247-90%0.160-84%0.208-88%
Usd Book Value Per Share--5.8365.659+3%4.852+20%3.978+47%3.624+61%
Usd Dividend Per Share---0.026-100%0.054-100%0.055-100%0.049-100%
Usd Eps--0.1210.191-37%0.215-44%0.129-6%0.084+44%
Usd Free Cash Flow--2128641.7251455394.623+46%356725.709+497%904272.507+135%670178.898+218%
Usd Free Cash Flow Per Share--0.1980.135+46%0.034+489%0.082+140%0.061+224%
Usd Free Cash Flow To Equity Per Share--0.1980.105+88%-0.059+130%0.033+497%0.016+1129%
Usd Market Cap43371790.000-3%44804982.22245973561.582-3%45459395.363-1%47533564.011-6%44088284.972+2%
Usd Price Per Share4.025-3%4.1584.265-3%4.181-1%4.306-3%3.982+4%
Usd Profit--1306708.8092058987.912-37%2336597.891-44%1410639.679-7%917473.973+42%
Usd Revenue--19108825.23217333570.261+10%14170259.976+35%12076068.878+58%10910564.447+75%
Usd Total Gains Per Share--0.0250.207-88%0.300-92%0.214-88%0.257-90%
 EOD+4 -4MRQTTM+16 -18YOY+16 -195Y+16 -1910Y+25 -10

3.2. Fundamental Score

Let's check the fundamental score of Jin Yang Pharmaceutical Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.298
Price to Book Ratio (EOD)Between0-10.690
Net Profit Margin (MRQ)Greater than00.068
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.004
Current Ratio (MRQ)Greater than11.853
Debt to Asset Ratio (MRQ)Less than10.277
Debt to Equity Ratio (MRQ)Less than10.383
Return on Equity (MRQ)Greater than0.150.021
Return on Assets (MRQ)Greater than0.050.015
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Jin Yang Pharmaceutical Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.641
Ma 20Greater thanMa 505,472.000
Ma 50Greater thanMa 1005,383.000
Ma 100Greater thanMa 2005,536.100
OpenGreater thanClose5,660.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets124,281,033
Total Liabilities34,450,032
Total Stockholder Equity89,831,001
 As reported
Total Liabilities 34,450,032
Total Stockholder Equity+ 89,831,001
Total Assets = 124,281,033

Assets

Total Assets124,281,033
Total Current Assets52,773,193
Long-term Assets71,507,840
Total Current Assets
Cash And Cash Equivalents 4,676,282
Short-term Investments 6,536,954
Net Receivables 22,046,422
Inventory 18,936,914
Other Current Assets 1
Total Current Assets  (as reported)52,773,193
Total Current Assets  (calculated)52,196,573
+/- 576,621
Long-term Assets
Property Plant Equipment 43,778,372
Intangible Assets 6,501,069
Long-term Assets Other 1
Long-term Assets  (as reported)71,507,840
Long-term Assets  (calculated)50,279,442
+/- 21,228,398

Liabilities & Shareholders' Equity

Total Current Liabilities28,478,090
Long-term Liabilities5,971,942
Total Stockholder Equity89,831,001
Total Current Liabilities
Short Long Term Debt 8,039,495
Accounts payable 3,590,560
Total Current Liabilities  (as reported)28,478,090
Total Current Liabilities  (calculated)11,630,055
+/- 16,848,035
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt291,386
Long-term Liabilities  (as reported)5,971,942
Long-term Liabilities  (calculated)291,386
+/- 5,680,556
Total Stockholder Equity
Retained Earnings 62,396,142
Total Stockholder Equity (as reported)89,831,001
Total Stockholder Equity (calculated)62,396,142
+/- 27,434,859
Other
Capital Stock6,008,439
Common Stock Shares Outstanding 10,776
Net Debt 3,363,213
Net Invested Capital 97,870,496
Net Working Capital 24,295,103
Property Plant and Equipment Gross 66,002,822



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
> Total Assets 
77,723,716
80,288,068
73,848,507
69,393,660
72,935,822
69,767,858
70,061,148
71,263,176
73,438,968
66,396,276
68,277,806
68,074,904
67,385,924
66,872,970
68,076,494
69,818,555
68,873,249
85,722,773
98,501,761
102,140,160
101,913,771
112,874,839
114,443,691
118,113,200
121,411,185
123,682,157
119,906,620
124,281,033
124,281,033119,906,620123,682,157121,411,185118,113,200114,443,691112,874,839101,913,771102,140,16098,501,76185,722,77368,873,24969,818,55568,076,49466,872,97067,385,92468,074,90468,277,80666,396,27673,438,96871,263,17670,061,14869,767,85872,935,82269,393,66073,848,50780,288,06877,723,716
   > Total Current Assets 
26,648,633
30,358,786
23,429,112
28,381,083
31,370,678
28,720,693
29,836,411
31,355,483
33,582,713
26,912,787
28,082,027
27,989,287
27,335,881
26,975,834
28,711,843
29,501,189
27,999,033
28,734,051
41,004,709
45,882,307
45,697,786
46,297,027
46,328,553
49,649,609
53,491,229
56,036,866
48,028,761
52,773,193
52,773,19348,028,76156,036,86653,491,22949,649,60946,328,55346,297,02745,697,78645,882,30741,004,70928,734,05127,999,03329,501,18928,711,84326,975,83427,335,88127,989,28728,082,02726,912,78733,582,71331,355,48329,836,41128,720,69331,370,67828,381,08323,429,11230,358,78626,648,633
       Cash And Cash Equivalents 
344,476
1,115,577
109,627
4,866,466
4,755,931
744,884
86,431
1,202,429
6,733,821
388,283
1,711,564
1,372,978
3,489,111
2,138,436
5,175,431
4,586,884
2,401,613
585,493
11,719,863
0
0
0
753,556
3,050,814
2,404,049
3,614,411
5,118,099
4,676,282
4,676,2825,118,0993,614,4112,404,0493,050,814753,55600011,719,863585,4932,401,6134,586,8845,175,4312,138,4363,489,1111,372,9781,711,564388,2836,733,8211,202,42986,431744,8844,755,9314,866,466109,6271,115,577344,476
       Short-term Investments 
200,000
800,000
1,400,000
2,000,000
1,000,000
1,600,000
2,200,000
2,800,000
0
2,700,000
3,115,000
0
0
1,291,575
149,753
159,430
149,457
1,252,381
3,155,068
15,008,568
11,748,160
3,763,490
9,740,809
8,924,600
7,396,476
9,662,347
3,477,274
6,536,954
6,536,9543,477,2749,662,3477,396,4768,924,6009,740,8093,763,49011,748,16015,008,5683,155,0681,252,381149,457159,430149,7531,291,575003,115,0002,700,00002,800,0002,200,0001,600,0001,000,0002,000,0001,400,000800,000200,000
       Net Receivables 
17,969,060
19,609,080
14,872,967
14,204,937
16,606,758
16,912,857
18,859,613
18,582,977
17,949,872
12,772,687
15,808,809
14,822,354
14,973,632
15,667,763
15,441,390
15,541,452
17,596,800
17,660,816
16,683,639
18,268,078
19,007,672
22,459,745
20,247,883
21,334,190
23,171,258
22,548,373
21,711,476
22,046,422
22,046,42221,711,47622,548,37323,171,25821,334,19020,247,88322,459,74519,007,67218,268,07816,683,63917,660,81617,596,80015,541,45215,441,39015,667,76314,973,63214,822,35415,808,80912,772,68717,949,87218,582,97718,859,61316,912,85716,606,75814,204,93714,872,96719,609,08017,969,060
       Inventory 
7,923,218
7,878,837
6,826,834
6,896,789
7,105,715
8,058,695
7,250,247
7,378,131
7,077,542
6,862,904
6,694,988
7,834,779
6,999,153
7,745,174
7,873,985
8,999,111
7,806,284
9,186,185
9,060,030
9,658,836
12,418,936
13,191,542
15,423,409
16,088,548
19,170,325
19,005,708
17,352,805
18,936,914
18,936,91417,352,80519,005,70819,170,32516,088,54815,423,40913,191,54212,418,9369,658,8369,060,0309,186,1857,806,2848,999,1117,873,9857,745,1746,999,1537,834,7796,694,9886,862,9047,077,5427,378,1317,250,2478,058,6957,105,7156,896,7896,826,8347,878,8377,923,218
       Other Current Assets 
12,220
783,496
1,693
233,755
271,932
74,644
120,458
218,262
100,057
79,390
88,972
136,339
80,875
119,584
40,169
189,862
26,396
35,461
0
0
29,496
26,929
120,066
0
0
0
0
1
10000120,06626,92929,4960035,46126,396189,86240,169119,58480,875136,33988,97279,390100,057218,262120,45874,644271,932233,7551,693783,49612,220
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
68,115,138
68,463,591
67,919,956
67,645,291
71,877,858
71,507,840
71,507,84071,877,85867,645,29167,919,95668,463,59168,115,1380000000000000000000000
       Property Plant Equipment 
39,402,247
38,275,625
29,149,918
28,712,504
30,333,234
29,923,121
29,518,794
29,125,837
29,201,210
28,870,001
28,504,968
28,266,389
28,127,491
28,218,723
27,760,885
28,310,062
28,438,282
39,791,231
39,363,404
38,819,608
38,673,308
44,581,359
43,793,696
43,600,398
42,290,171
41,941,570
44,136,285
43,778,372
43,778,37244,136,28541,941,57042,290,17143,600,39843,793,69644,581,35938,673,30838,819,60839,363,40439,791,23128,438,28228,310,06227,760,88528,218,72328,127,49128,266,38928,504,96828,870,00129,201,21029,125,83729,518,79429,923,12130,333,23428,712,50429,149,91838,275,62539,402,247
       Long Term Investments 
2,636,958
2,708,780
2,766,230
1,864,429
1,125,511
1,125,720
1,125,117
1,161,762
1,167,327
1,175,345
2,465,620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,465,6201,175,3451,167,3271,161,7621,125,1171,125,7201,125,5111,864,4292,766,2302,708,7802,636,958
       Intangible Assets 
1,761,456
1,757,308
1,753,160
1,749,012
1,494,864
1,490,728
1,487,383
1,485,586
1,483,812
1,498,537
1,497,762
1,515,487
1,514,712
1,511,179
1,509,504
1,709,913
1,893,131
1,881,563
1,869,995
1,858,427
1,941,659
3,230,091
4,979,819
5,498,196
6,835,742
6,911,416
6,516,023
6,501,069
6,501,0696,516,0236,911,4166,835,7425,498,1964,979,8193,230,0911,941,6591,858,4271,869,9951,881,5631,893,1311,709,9131,509,5041,511,1791,514,7121,515,4871,497,7621,498,5371,483,8121,485,5861,487,3831,490,7281,494,8641,749,0121,753,1601,757,3081,761,456
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
1
1101000000000000000000000000
> Total Liabilities 
29,304,921
31,395,614
31,467,236
28,054,794
30,856,979
27,228,964
28,013,282
29,070,599
30,578,069
23,748,779
24,611,584
25,192,524
23,630,378
21,793,529
21,765,674
23,871,059
19,014,777
20,736,637
33,183,979
36,237,353
32,903,389
36,949,341
36,868,552
39,390,368
38,793,047
37,151,688
30,323,188
34,450,032
34,450,03230,323,18837,151,68838,793,04739,390,36836,868,55236,949,34132,903,38936,237,35333,183,97920,736,63719,014,77723,871,05921,765,67421,793,52923,630,37825,192,52424,611,58423,748,77930,578,06929,070,59928,013,28227,228,96430,856,97928,054,79431,467,23631,395,61429,304,921
   > Total Current Liabilities 
12,271,000
27,151,513
27,246,934
23,640,794
26,242,327
22,418,555
23,153,341
23,999,308
25,692,392
18,951,755
19,926,066
20,422,354
18,783,908
17,046,725
16,952,419
18,908,833
13,914,822
13,173,672
27,143,034
31,770,879
28,603,311
30,736,672
30,937,794
33,474,546
32,931,924
31,235,167
24,511,035
28,478,090
28,478,09024,511,03531,235,16732,931,92433,474,54630,937,79430,736,67228,603,31131,770,87927,143,03413,173,67213,914,82218,908,83316,952,41917,046,72518,783,90820,422,35419,926,06618,951,75525,692,39223,999,30823,153,34122,418,55526,242,32723,640,79427,246,93427,151,51312,271,000
       Short-term Debt 
17,240,864
17,000,000
17,000,000
16,000,000
16,000,000
11,980,000
11,980,000
11,980,000
11,980,000
9,000,000
9,000,000
8,000,000
8,000,000
6,000,000
6,000,000
5,000,000
2,947,078
2,706,387
632,198
635,338
687,008
598,707
664,857
945,927
523,223
0
0
0
000523,223945,927664,857598,707687,008635,338632,1982,706,3872,947,0785,000,0006,000,0006,000,0008,000,0008,000,0009,000,0009,000,00011,980,00011,980,00011,980,00011,980,00016,000,00016,000,00017,000,00017,000,00017,240,864
       Short Long Term Debt 
17,240,864
17,000,000
17,000,000
16,000,000
16,000,000
11,980,000
11,980,000
11,980,000
11,980,000
9,000,000
0
0
0
0
0
0
0
0
0
0
0
0
9,910,036
10,518,352
10,441,226
10,795,497
7,525,069
8,039,495
8,039,4957,525,06910,795,49710,441,22610,518,3529,910,0360000000000009,000,00011,980,00011,980,00011,980,00011,980,00016,000,00016,000,00017,000,00017,000,00017,240,864
       Accounts payable 
2,756,903
3,484,111
2,850,473
2,087,930
3,408,775
3,769,872
2,808,106
2,743,897
3,204,726
2,769,714
3,344,633
3,354,327
2,571,783
3,057,895
2,723,936
3,141,145
2,317,309
1,934,535
0
0
3,127,122
3,758,374
2,536,022
3,174,426
4,565,292
2,707,418
2,443,942
3,590,560
3,590,5602,443,9422,707,4184,565,2923,174,4262,536,0223,758,3743,127,122001,934,5352,317,3093,141,1452,723,9363,057,8952,571,7833,354,3273,344,6332,769,7143,204,7262,743,8972,808,1063,769,8723,408,7752,087,9302,850,4733,484,1112,756,903
       Other Current Liabilities 
4,216,461
3,296,185
3,489,411
4,336,178
5,616,634
5,565,573
6,129,295
7,224,110
5,673,024
5,328,202
5,397,502
6,888,822
6,076,555
5,708,657
5,591,199
7,915,048
5,663,225
5,546,800
0
0
4,911,973
5,939,850
6,427,896
1
0
2
0
0
002016,427,8965,939,8504,911,973005,546,8005,663,2257,915,0485,591,1995,708,6576,076,5556,888,8225,397,5025,328,2025,673,0247,224,1106,129,2955,565,5735,616,6344,336,1783,489,4113,296,1854,216,461
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,930,758
5,915,822
5,861,123
5,916,522
5,812,153
5,971,942
5,971,9425,812,1535,916,5225,861,1235,915,8225,930,7580000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
109,278
92,436
75,441
58,292
40,988
55,772
60,569
45,003
0
64,736
153,156
297,928
253,461
209,364
167,767
0
0
0
000167,767209,364253,461297,928153,15664,736045,00360,56955,77240,98858,29275,44192,436109,2780000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451,906
420,713
377,528
341,628
306,208
291,386
291,386306,208341,628377,528420,713451,9060000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,407,171
0
0
0
0
0
000001,407,1710000000000000000000000
> Total Stockholder Equity
48,418,795
48,892,454
42,381,271
41,338,866
42,078,843
42,538,894
42,047,866
42,192,576
42,860,899
42,647,497
43,666,222
42,882,380
43,755,546
45,079,441
46,310,820
45,947,496
49,858,473
64,986,137
65,317,782
65,902,808
69,010,382
75,925,498
77,575,139
78,722,832
82,618,138
86,530,469
89,583,433
89,831,001
89,831,00189,583,43386,530,46982,618,13878,722,83277,575,13975,925,49869,010,38265,902,80865,317,78264,986,13749,858,47345,947,49646,310,82045,079,44143,755,54642,882,38043,666,22242,647,49742,860,89942,192,57642,047,86642,538,89442,078,84341,338,86642,381,27148,892,45448,418,795
   Common Stock
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
6,000,000
0
0
0
0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,0006,000,000
   Retained Earnings 
33,133,064
33,606,790
27,095,566
26,052,811
26,792,924
27,252,812
27,287,254
27,431,630
28,100,115
27,886,954
27,908,315
27,124,473
27,997,638
29,321,533
30,399,634
30,036,311
33,997,793
36,105,148
40,625,624
41,210,649
44,318,224
50,486,105
51,883,862
53,031,472
58,011,078
61,923,409
62,148,573
62,396,142
62,396,14262,148,57361,923,40958,011,07853,031,47251,883,86250,486,10544,318,22441,210,64940,625,62436,105,14833,997,79330,036,31130,399,63429,321,53327,997,63827,124,47327,908,31527,886,95428,100,11527,431,63027,287,25427,252,81226,792,92426,052,81127,095,56633,606,79033,133,064
   Capital Surplus 
0
0
0
0
0
0
0
0
0
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
9,601,233
0
0
0
0009,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,2339,601,233000000000
   Treasury Stock000000000-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214-3,069,214000000000
   Other Stockholders Equity 
2,729,644
2,729,577
2,729,619
2,729,968
2,729,832
2,729,995
2,204,525
2,204,859
2,204,697
24,068
3,201,821
3,201,821
3,201,821
3,201,821
3,355,099
3,355,099
3,304,592
16,324,902
24,068
24,068
12,136,071
15,457,419
15,709,304
24,068
24,068
0
0
0
00024,06824,06815,709,30415,457,41912,136,07124,06824,06816,324,9023,304,5923,355,0993,355,0993,201,8213,201,8213,201,8213,201,82124,0682,204,6972,204,8592,204,5252,729,9952,729,8322,729,9682,729,6192,729,5772,729,644



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue94,111,138
Cost of Revenue-36,651,936
Gross Profit57,459,20257,459,202
 
Operating Income (+$)
Gross Profit57,459,202
Operating Expense-85,026,034
Operating Income9,085,104-27,566,832
 
Operating Expense (+$)
Research Development0
Selling General Administrative34,898,452
Selling And Marketing Expenses0
Operating Expense85,026,03434,898,452
 
Net Interest Income (+$)
Interest Income396,613
Interest Expense-1,373,826
Other Finance Cost-210,195
Net Interest Income-767,018
 
Pretax Income (+$)
Operating Income9,085,104
Net Interest Income-767,018
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,583,3779,085,104
EBIT - interestExpense = -1,373,826
12,659,155
14,032,981
Interest Expense1,373,826
Earnings Before Interest and Taxes (EBIT)013,957,203
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax12,583,377
Tax Provision--75,779
Net Income From Continuing Ops12,659,15512,659,155
Net Income12,659,155
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0767,018
 

Technical Analysis of Jin Yang Pharmaceutical Co. Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jin Yang Pharmaceutical Co. Ltd. The general trend of Jin Yang Pharmaceutical Co. Ltd is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jin Yang Pharmaceutical Co. Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jin Yang Pharmaceutical Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5,700 < 5,700 < 5,708.

The bearish price targets are: 5,250 > 5,250 > 5,020.

Tweet this
Jin Yang Pharmaceutical Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jin Yang Pharmaceutical Co. Ltd. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jin Yang Pharmaceutical Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jin Yang Pharmaceutical Co. Ltd. The current macd is 69.88.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Jin Yang Pharmaceutical Co. Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Jin Yang Pharmaceutical Co. Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Jin Yang Pharmaceutical Co. Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Jin Yang Pharmaceutical Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartJin Yang Pharmaceutical Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jin Yang Pharmaceutical Co. Ltd. The current adx is 42.10.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Jin Yang Pharmaceutical Co. Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Jin Yang Pharmaceutical Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jin Yang Pharmaceutical Co. Ltd. The current sar is 5,835.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jin Yang Pharmaceutical Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jin Yang Pharmaceutical Co. Ltd. The current rsi is 62.64. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Jin Yang Pharmaceutical Co. Ltd Daily Relative Strength Index (RSI) ChartJin Yang Pharmaceutical Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jin Yang Pharmaceutical Co. Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Jin Yang Pharmaceutical Co. Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Jin Yang Pharmaceutical Co. Ltd Daily Stochastic Oscillator ChartJin Yang Pharmaceutical Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jin Yang Pharmaceutical Co. Ltd. The current cci is 165.58.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Jin Yang Pharmaceutical Co. Ltd Daily Commodity Channel Index (CCI) ChartJin Yang Pharmaceutical Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jin Yang Pharmaceutical Co. Ltd. The current cmo is 32.41.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Jin Yang Pharmaceutical Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartJin Yang Pharmaceutical Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jin Yang Pharmaceutical Co. Ltd. The current willr is -5.66037736.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Jin Yang Pharmaceutical Co. Ltd Daily Williams %R ChartJin Yang Pharmaceutical Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jin Yang Pharmaceutical Co. Ltd.

Jin Yang Pharmaceutical Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jin Yang Pharmaceutical Co. Ltd. The current atr is 150.53.

Jin Yang Pharmaceutical Co. Ltd Daily Average True Range (ATR) ChartJin Yang Pharmaceutical Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jin Yang Pharmaceutical Co. Ltd. The current obv is 4,659,359.

Jin Yang Pharmaceutical Co. Ltd Daily On-Balance Volume (OBV) ChartJin Yang Pharmaceutical Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jin Yang Pharmaceutical Co. Ltd. The current mfi is 72.14.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Jin Yang Pharmaceutical Co. Ltd Daily Money Flow Index (MFI) ChartJin Yang Pharmaceutical Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jin Yang Pharmaceutical Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-06-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Jin Yang Pharmaceutical Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jin Yang Pharmaceutical Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.641
Ma 20Greater thanMa 505,472.000
Ma 50Greater thanMa 1005,383.000
Ma 100Greater thanMa 2005,536.100
OpenGreater thanClose5,660.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jin Yang Pharmaceutical Co. Ltd with someone you think should read this too:
  • Are you bullish or bearish on Jin Yang Pharmaceutical Co. Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jin Yang Pharmaceutical Co. Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jin Yang Pharmaceutical Co. Ltd

I send you an email if I find something interesting about Jin Yang Pharmaceutical Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Jin Yang Pharmaceutical Co. Ltd.

Receive notifications about Jin Yang Pharmaceutical Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.